Dutasteride vs Trenbolone
FDA Approved vs Moderate Research
avoid Mechanism-based · 64% Both Dutasteride and Trenbolone carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.
Molecular Data
Dutasteride Trenbolone
Weight 528.53 Da 270.37 Da (base)
Half-life ~5 weeks (extremely long; active metabolite accumulation over months) ~3 days (acetate)
Type Synthetic 4-azasteroid compound (dual 5-alpha reductase inhibitor) 19-nortestosterone derivative (C18H22O2), trienone steroid
Key Benefits
Dutasteride
01 Inhibits both Type I and Type II 5-alpha reductase for more complete DHT suppression
02 Reduces serum DHT by approximately 90%, compared to 70% with finasteride
03 Head-to-head trials show superior hair count improvements over finasteride at 12 and 24 weeks
04 FDA-approved for BPH with well-established long-term safety data
05 Extremely long half-life allows for flexible dosing schedules (daily or 3x per week)
06 Convenient once-daily oral dosing with no injections required
07 Can be combined with minoxidil for enhanced hair loss treatment
Trenbolone
01 Exceptional lean muscle mass accrual with minimal water retention due to non-aromatizing profile
02 Dramatic body recomposition capability -- simultaneous muscle gain and fat loss even in caloric deficit
03 Approximately five times the anabolic and androgenic potency of testosterone (500:500 ratio)
04 Powerful anti-catabolic effects through glucocorticoid receptor antagonism, protecting muscle during dieting
05 Significant increases in strength across all compound movements, often rapid in onset
06 Enhanced nutrient partitioning, directing calories toward lean tissue accretion over fat storage
07 Pronounced muscle hardness, density, and vascularity due to absence of estrogenic water retention
08 Increased IGF-1 production in muscle tissue, amplifying growth signaling pathways
Dosing Protocols
Dutasteride
0.5mg/day / Once daily or 3x per week
Trenbolone
200-400 mg/week / Every other day (acetate) or 2x per week (enanthate)
Recomposition - Moderate (Acetate) 200-300 mg/week (50-75 mg every other day) Every other day
Advanced Cutting (Acetate) 300-400 mg/week (75-100 mg every other day) Every other day
Lean Bulk (Enanthate) 200-400 mg/week 2x per week
Contest Preparation - Advanced 300-500 mg/week Every other day (acetate) or 2x per week (enanthate)
Side Effects
Dutasteride
Decreased libido (reported in 3-5% of men; somewhat higher incidence than finasteride due to greater DHT suppression)
Erectile dysfunction (reported in 3-5%; more frequently reported than with finasteride)
Decreased ejaculate volume (reported in 1-2%)
Gynecomastia or breast tenderness (reported in approximately 1-2%)
Trenbolone
Insomnia and severely disrupted sleep architecture (one of the most universally reported side effects, affecting the majority of users)
Night sweats, often drenching, requiring sheet changes
Significantly reduced cardiovascular endurance and aerobic capacity
Increased aggression, irritability, and shortened temper
Anxiety and restlessness, particularly at higher doses
Tren cough: acute, intense coughing fit lasting 30-90 seconds immediately after injection, caused by a small amount of oil entering a blood vessel
Dark-colored urine (oxidized metabolites; not necessarily indicative of kidney damage but should be monitored)
Elevated body temperature and increased sweating throughout the day
Acne and oily skin, particularly on shoulders, back, and chest
Accelerated hair loss in those genetically predisposed to male pattern baldness
Profoundly suppressive of natural testosterone production (near-complete HPT axis shutdown)
Increased heart rate and elevated blood pressure
Contraindications
Women who are pregnant or may become pregnant (dutasteride is teratogenic and can cause abnormalities of external genitalia in a male fetus; even handling damaged capsules poses a risk due to skin absorption)
Women who are breastfeeding
Known hypersensitivity to dutasteride, other 5-alpha reductase inhibitors, or any component of the formulation
Severe hepatic impairment (dutasteride is extensively metabolized by the liver via CYP3A4)
Pediatric patients (not indicated for use in children)
Co-administration with strong CYP3A4 inhibitors (e.g., ritonavir, ketoconazole) may significantly increase dutasteride levels
First steroid cycle or limited anabolic steroid experience (trenbolone is strictly an advanced-only compound)
Pre-existing cardiovascular disease, cardiomyopathy, or significant cardiac risk factors
History of mental health conditions: anxiety disorders, depression, bipolar disorder, or psychotic episodes
Liver disease or significantly elevated liver enzymes
Kidney disease or impaired renal function
Uncontrolled hypertension
Polycythemia (hematocrit above 54% at baseline)
Prostate cancer or history of hormone-sensitive cancers
Active or recent substance abuse (trenbolone's psychological effects can exacerbate addictive behaviors)
Pregnancy or potential for pregnancy in female partners (extremely virilizing compound)
Research Evidence
Dutasteride Trenbolone
Status FDA Approved Moderate Research
References 5 studies 5 studies
Latest — January 2023
FDA Approved Yes No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.